No Data
No Data
Innovent Bio (01801.HK) has reached a cooperation with Insilico Medicine to establish an AI drug R&D platform.
Innovent bio (01801.HK) announced a recent collaboration with Wecomput to jointly promote the construction of the Innovent Bio National Qingyuan Computing Platform to accelerate the drug development process. It is expected to construct an efficient, easy-to-use, digital, intelligent, and automated one-stop AI drug development platform to reduce the cost of AI landing and experimental costs, shorten the drug development cycle, and improve the success rate of research and development, bringing more innovative drugs and treatment solutions to patients.
Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development
Innovent Bio is actively exploring the construction of an AI drug R&D platform, injecting new energy into drug research and development.
On July 26, 2024, San Francisco, USA and Suzhou, China / PR Newswire / - With the increase in global aging population and chronic diseases, there is an increasingly urgent need for new drug development. The traditional drug development process is time-consuming and expensive. The introduction of AI technology provides a new solution to this problem. Innovent Biologics has been committed to promoting industry development through technological innovation. Recently, Innovent Biologics announced its partnership with Weis Computing to jointly promote the construction and improvement of Innovent Biologics' Guoqing Institute computing platform. Through this cooperation, the two parties will integrate their respective advantages and technologies, and use AI technology to further accelerate drug development.
The table in the 'Da Hang' lists the predicted list of Hong Kong stocks that could turn 'blue'.
On August 16th, after the closing, Hang Seng Index Company will announce the results of the semi-annual review of the Hang Seng series of indices. ICBC listed a forecast list of possible 'blue dye' stocks: Stocks│ Possible Weighting │ Potential Passive Inflow of funds Kuaishou-W (01024.HK)│0.87%│0.224 billion USD Swireproperties (01972.HK)│0.41%│0.106 billion USD Innovent Bio (01801.HK)│0.35%│90.1 million USD Want Want China (00151.HK)│0.29%│74.7 million USD jd.com logistics (02
Zhongjin: Hang Seng Index to conduct mid-term review next month, Innovent Bio, Xiaopeng and others may be added to the list of eligible stocks for HK stock connect program. A total of 25 stocks are likely to be included.
According to a report released by CITIC Securities, after the market closes on August 16th, Hang Seng Index Company will announce the results of the semi-annual review of the Hang Seng series of indices, involving major flagship indices such as Hang Seng Index, HSI China Enterprises Index, Hang Seng Technology Index, as well as the Hang Seng Composite Index that is closely related to the investment scope of the Stock Connect. In terms of potential adjustment candidates, based on the adjustment method of the Hang Seng Index and the understanding and verification of the non-quantitative adjustment standards through the results of multiple actual adjustments in the past, the bank estimates Innovent Bio (01801.HK), Xpeng Inc. (09868.HK), JD Logistics (02618.HK), Want Want China (00151.HK), Miniso Group.
The Hong Kong stock index adjustment is coming soon. Which symbols may benefit?
Due to the large passive fund scale tracking flagship index, it is noteworthy to pay attention to potential changes in constituent stocks and corresponding capital trends.
No Data